Mochida Pharmaceutical Lifts FY2026 Forecast on Strong Q3 Performance and Expansion Plans
Mochida Pharmaceutical Co., Ltd. (TSE:4534), a mid-sized Japanese pharmaceutical company specializing in lipid-lowering drugs, reported robust third-quarter results for its fiscal year ending March 2026, driven by strong performance in its core products and positive outlook for future growth.
The company posted revenue of JPY 87.5bn, reflecting an 8.4% year-over-year increase, while operating profit rose 3.9% to JPY 7.53bn. Ordinary income increased by 9.2% to JPY 8.35bn, and net profit surged 13.2% to JPY 6.34bn. The operating margin of 8.6% highlights the company’s strong profitability, which outperforms the industry average.
Key Numbers
| Metric | Q3 2026 (JPY) | YoY Change |
|---|---|---|
| Revenue | 87.5bn | +8.4% |
| Operating Profit | 7.53bn | +3.9% |
| Ordinary Income | 8.35bn | +9.2% |
| Net Profit | 6.34bn | +13.2% |
| Operating Margin | 8.6% | — |
| Equity Ratio | 75.4% | — |
Business Overview
Mochida Pharmaceutical is a mid-sized player in the Japanese pharmaceutical industry, with a strong focus on lipid-lowering drugs, antihypertensive medications, and gynecological products. The company is also expanding into the healthcare sector, positioning itself for long-term growth.
Analysis
Mochida Pharmaceutical’s performance in Q3 2026 reflects strong execution across its core business segments. The company’s operating margin of 8.6% is notably higher than the industry average of 6.0%, indicating effective cost management and strong pricing power in its key markets. This is particularly impressive given the highly competitive nature of the pharmaceutical sector.
The growth in net profit outpaced that of operating and ordinary income, suggesting improvements in the company’s overall efficiency and profit structure. This could be attributed to a higher proportion of high-margin products in its sales mix or cost reductions in fixed expenses.
Looking ahead, the company has set targets for the next fiscal year. Management expects revenue to rise to JPY 115.5bn, representing a 9.8% increase versus full-year FY2026. Operating profit is forecast to reach JPY 9.5bn, up 16.9% year-over-year, while net profit is expected to climb to JPY 8.4bn, a 47.8% increase. These targets reflect steady top-line growth and a significant improvement in bottom-line profitability.
Next Year Guidance
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.